药物诱导的骨质疏松症
Rudolf Wolfgang Gasser1, Roland Kocijan2,3, Afrodite Zendeli3
1Department of Internal Medicine I, Medical University of Innsbruck, 6020 Innsbruck, Austria.
某些药物可以导致药物诱导的骨质疏松症,增加骨折风险. 在长期处方这些药物时,积极的骨健康评估和管理至关重要,特别是在老年人中.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 骨生物学 骨生物学 骨生物学
背景情况:
- 药物可以导致骨质损失作为副作用,导致药物诱导的骨质疏松症.
- 这种情况是二次骨质疏松症的重要原因,并增加骨折风险.
研究的目的:
- 审查常用的药物对骨代谢,骨矿物质密度和骨折结果的骨影响.
- 突出与药物诱导骨质疏松症相关的药物类别,并讨论管理策略.
主要方法:
- 对选定的常用药物的文献综述.
- 药物诱导的骨损失的直接和间接机制的总结.
- 讨论临床影响,包括骨折风险评估和管理.
主要成果:
- 药物可以通过直接影响骨质母细胞/骨质母细胞或间接通过代谢障碍 (,维生素D,激素) 损害骨重塑.
- 涉及的关键药物类别包括葡萄糖皮质类药物,芳酶抑制剂,抗雄激素剥夺疗法,甲状腺素,PPI,抗凝固剂,抗抑郁药,神经质障碍药和 thiazolidinediones.
- 长期使用,特别是老年人,需要积极考虑骨健康问题.
结论:
- 药物诱导的骨质疏松症是一种临床相关的不良影响,需要谨慎管理.
- 建议进行主动评估,包括实验室测试,骨折风险估计 (例如,FRAX®) 和骨质量测量.
- 确保足够的和维生素D摄入量以及启动基于指南的治疗对于服用骨损伤药物的患者至关重要.
更多相关视频
06:59Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
Published on: September 8, 2023
03:56Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
相关概念视频
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Bioequivalence of Drugs: Drugs with Multiple Indications
FDA Approved Drugs: Changes to Approved Drugs
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Tissue-Drug Binding: Localization of Drugs and its Significance
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
